SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
Conclusions
nab-Paclitaxel accumulates and acts in a dose-dependent manner. The interaction of plasma SPARC and albumin-bound drugs is observed at low doses of nab-paclitaxel but is saturated at therapeutic doses in murine tumours. Thus, this study provides important information for future preclinical and clinical trials in PDA using nab-paclitaxel in combination with novel experimental and targeted agents.
Source: Gut - Category: Gastroenterology Authors: Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., Ellenrieder, V., Jodrell, D. I., Tuveson, D. A. Tags: Pancreas and biliary tract, Open access Pancreatic cancer Source Type: research
More News: Abraxane | Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Gastroenterology | Genetics | Pancreas | Pancreatic Cancer | Study | Toxicology | Ultrasound